COMMUNIQUÉS West-GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - March 2025
02/05/2025
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Mars 2025
02/05/2025
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
CARBIOS files its 2024 Universal Registration Document
02/05/2025
Clermont-Ferrand (France), May 2, 2025 (6:00 pm CEST). CARBIOS , (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and [...]
CARBIOS annonce la mise à disposition de son Document d’enregistrement universel 2024
02/05/2025
Clermont-Ferrand (France), le 2 mai 2025 (18h00 CEST). CARBIOS, (Euronext Growth Paris : ALCRB), pionnière dans le développement et l'industrialisation de technologies biologiques pour réinventer le cycle de vie des [...]
Trial Finds Inquis Medical’s AVENTUS Thrombectomy System Safe and Effective for Patients with Pulmonary Embolism
02/05/2025
Results of AVENTUS IDE Trial presented at SCAI Scientific Sessions MENLO PARK, Calif. and WASHINGTON, May 02, 2025 (GLOBE NEWSWIRE) -- Inquis Medical , a leading innovator in venous thromboembolic disease treatment, [...]
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds
02/05/2025
GLEN ALLEN, Va., May 02, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“ Adial ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment [...]
Prime Biome Reviews (URGENT DOCTOR REPORT) Unexpected Gut Benefits And Side Effects Reported By Real Users!
02/05/2025
ALBANY, N.Y., May 02, 2025 (GLOBE NEWSWIRE) -- Gut health and skin care have always been treated as separate issues, with people relying on skincare products for clearer skin and digestive aids for bloating or [...]
International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers
02/05/2025
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome [...]
Hapbee Technologies Partners with Snooze - the Fastest-Growing Sleep & Wellness Retailer in the U.S. - to Expand Experiential Retail Footprint
02/05/2025
VANCOUVER, British Columbia, May 02, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies Inc. (TSXV: HAPB | OTCQB: HAPBF | FSE: HA1) (“Hapbee” or the “Company”), the digital wellness company pioneering bio-streamed wearable [...]
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)
02/05/2025
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first [...]
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT
02/05/2025
REYKJAVIK, Iceland, May 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that [...]
Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
02/05/2025
MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]
SS Innovations Announces Chief Financial Officer Transition
02/05/2025
FORT LAUDERDALE, Fla., May 02, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII) , a developer of innovative surgical robotic technologies dedicated to making [...]
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
02/05/2025
On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025: EMERALD for broad [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
02/05/2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 2 May 2025 at 15.15 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Repeat: EnteroBiotix to Present Results from Phase 1b trial in Liver Cirrhosis at EASL Congress 2025
02/05/2025
Glasgow, Scotland – 2 May 2025. EnteroBiotix Limited (‘EnteroBiotix’), a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, today announced that results from its IMPuLCE [...]
Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results
02/05/2025
MALVERN, Pa., May 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02/05/2025
DALLAS, May 02, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians
02/05/2025
Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million upfront and ALK with commercialization rights to neffy in Canada, United Kingdom, European [...]

Pages